IQVIA Holdings Inc. – Consensus ‘buy’ rating and 12.4% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

IQVIA Holdings Inc. which can be found using ticker (IQV) have now 19 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $265.00 and $190.00 calculating the average target price we see $225.37. Now with the previous closing price of $200.48 this would indicate that there is a potential upside of 12.4%. It’s also worth noting that there is a 50 day moving average of $197.87 while the 200 day moving average is $206.76. The market cap for the company is 37.56B. The stock price for the company is currently $205.83 USD

The potential market cap would be $42,227,617,405 based on the market consensus.

The company has a dividend yield of 2.93%. Other points of data to note are a P/E ratio of 34.48, revenue per share of $80.44 and a 4.9% return on assets.

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search